The EGFR and ERBB3 are overexpressed in 50–70% of lung, colon and breast carcinoma; ERBB2 is overexpressed in 30% of breast cancer patients; ERBB4 is expressed in 50% of breast cancer patients and 22% of colon cancer patients. This evidence concerns the gene ERBB4 and breast carcinoma.